Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
LUPKYNIS® Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting
Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting
